We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App





CerTest Demonstrates VIASURE Real Time PCR Complete Solution at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023

CerTest Biotec (Zaragoza, Spain) is presenting several novel products for research and diagnosis at Medlab Middle East 2023, including its VIASURE Real Time PCR Complete Solution, along with equipment and reagents for CLIA. More...

The VIASURE Complete Solution comprises the VIASURE RNA/DNA extraction kits, the V-FLEX nucleic acid extraction and PCR set-up system, V-Lab96 Real Time PCR system and V-Smart automatic interpretation software.

The VIASURE V-FLEX system is a fully automated solution in molecular biology for nucleic acid extraction, purification and PCR set-up from biological matrix and samples. The instrument has been designed with flexible configuration, in order to meet different user needs. The VIASURE V-Lab96 Advanced Real Time PCR System with 96-well block for high sample throughput in diagnostic lab applications. VIASURE V-Lab96 allows users to analyze 96 samples simultaneously for qualitative and quantitative PCR. The VIASURE V-Smart software for the analysis and interpretation of VIASURE RT PCR assays facilitates the conversion of the PCR raw data into test results with minimal manual intervention. Additionally, VIASURE Real Time PCR Detection Kits allow for simultaneous detection of multiple targets in a broad range of multiplexing diagnostic panels, including in the area of antimicrobial resistance.

Recently, CerTest had announced that the company will run its campaign ‘More than Diagnostics’ throughout 2023 in acknowledgement of the transformation that it has gone through, accelerated by the COVID-19 pandemic. CerTest’s ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future, with people’s health remaining its key focus.

Related Links:
CerTest Biotec


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.